

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China Regenerative Medicine International Limited**

**中國再生醫學國際有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8158)**

### **CONNECTED TRANSACTION – LOAN CAPITALISATION INVOLVING ISSUE OF SHARES UNDER SPECIFIC MANDATE EXTENSION OF LONG-STOP DATE**

References are made to the announcement of China Regenerative Medicine International Limited (the “**Company**”) dated 14 July 2023 and the circular (the “**Circular**”) of the Company dated 18 August 2023 in relation to, among other things, Capital Reorganisation and the Loan Capitalisation. Capitalised terms used in this announcement shall have the same meaning as those used in the Circular unless otherwise defined.

Pursuant to the Subscription Agreement, Completion is conditional upon the fulfillment of the conditions precedent to the Subscription Agreement on or before the Long-stop Date, being on the expiry of three (3) months after the date of the Subscription Agreement or such other date as the parties hereto may agree in writing. As additional time is required for the fulfilment of the conditions precedent, the parties thereto entered into a supplemental agreement on 12 October 2023, pursuant to which the parties agreed to revise the Long-stop Date to on the expiry of six (6) months after the date of the Subscription Agreement or such other date as the parties hereto may agree in writing.

Save for above extension of the Long-stop Date, all other terms of the Subscription Agreement shall remain unchanged and continue in full force and effect. The Company is of the view that the extension of the Long-stop Date would not have any material adverse impact on the business and performance of the Group.

By Order of the Board  
**China Regenerative Medicine International Limited**  
**Khoo Wun Fat William**  
*Company Secretary*

Hong Kong, 12 October 2023

*As at the date of this announcement, the executive Director is Mr. Wang Chuang (Chairman and Chief Executive Officer); the non-executive Director is Mr. Tsang Ho Yin; and the independent non-executive Directors are Ms. Huo Chunyu, Dr. Liu Ming and Mr. Leung Man Fai.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of its publication. This announcement will also be published on the Company’s website at [www.crimi.hk](http://www.crimi.hk).*

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*